CytomX Therapeutics

CTMX

Market cap $725M

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December.

CytomX Therapeutics (CTMX) is highlighted as a Buy, driven by optimism for its masked antibody probody platform targeting cancer. Lead candidate CX-2051 shows promising phase 1 results in refractory colorectal cancer, with disease control in nearly all patients and confirmed responses. CTMX holds a strong financial position with $34.2 million in cash and $109.4 million in investments, supporting operations through Q2 2027.

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:00 a.m. GMT.

CytomX (CTMX) is advancing its ADC candidate CX-2051 in the oncological field. CX-2051 shows an impressive response rate and improved progression-free survival in heavily pretreated colorectal cancer patients, outperforming current therapies. Investment in CTMX is high risk and binary, but promising science and early clinical data support a speculative Buy for risk-tolerant investors.

CytomX Therapeutics, Inc. ( CTMX ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Chris Ogden - SVP & Chief Financial Officer Sean McCarthy - Chairman & CEO Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Matthew Biegler - Oppenheimer & Co. Inc., Research Division Etzer Darout - Barclays Bank PLC, Research Division Mitchell Kapoor - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, everyone.

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.07 per share a year ago.

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m.

Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launching premature IPOs.

- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.